Why didn't Medtronic recall sooner?

Big cardiac clinics across the country stopped using Medtronic's Fidelis defibrillator lead in early February because they considered it unsafe. So why did the company wait till October to recall it? And why did it blame doctors' technique for some of the malfunctions?

Those are the questions the Wall Street Journal poses today in a piece that not only questions Medtronic's actions, but also the FDA's system for regulating medical devices, which aren't subject to the stringent testing prescription drugs undergo before hitting the market.

- read the article in the Wall Street Journal (sub. req.)

Related Articles:
Medtronic recall spawns inquiry. Report
Did patient lawsuit spur Medtronic recall? Report
Medtronic withdraws defibrillator part. Report
Medtronic's fortunes depend on new stent. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.